Trial Profile

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Vorinostat (Primary) ; Crisantaspase; Crisantaspase; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Hydrocortisone; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase; Pegaspargase
Indications Haematological malignancies; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

05 Jan 2017 Planned End Date changed from 1 Apr 2029 to 1 Oct 2026.
05 Jan 2017 Status changed from recruiting to discontinued as accrual goals were no longer feasible based on restrictions imposed by the DSMB.
21 Apr 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com